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Abstract
Breast cancer progression is associated with systemic effects including functional limitations and 
sarcopenia without the appearance of overt cachexia. Autocrine/paracrine actions of cytokines/
chemokines produced by cancer cells mediate cancer progression and functional limitations. The 
cytokine-inducible transcription factor NF-κB could be central to this process, as it displays 
oncogenic functions and is integral to the Pax7:MyoD:Pgc-1β:miR-486 myogenesis axis. We 
tested this possibility using the MMTV-PyMT transgenic mammary tumor model and the NF-κB 
inhibitor dimethylaminoparthenolide (DMAPT). We observed deteriorating physical and 
functional conditions in PyMT+ mice with disease progression. Compared to wild type mice, 
tumor-bearing PyMT+ mice showed decreased fat mass, impaired rotarod performance, and 
reduced grip strength as well as increased extracellular matrix (ECM) deposition in muscle. 
Contrary to acute cachexia models described in the literature, mammary tumor progression was 
associated with reduction in skeletal muscle stem/satellite-specific transcription factor Pax7. 
Additionally, we observed tumor-induced reduction in Pgc-1β in muscle, which controls 
mitochondrial biogenesis. DMAPT treatment starting at 6-8 weeks age prior to mammary tumor 
occurrence delayed mammary tumor onset and tumor growth rates without affecting metastasis. 
DMAPT overcame cancer-induced functional limitations and improved survival, which was 
accompanied with restoration of Pax7, Pgc-1β, and mitochondria levels and reduced ECM levels 
in skeletal muscles. In addition, DMAPT restored circulating levels of six out of 13 cancer-
associated cytokines/chemokines changes to levels seen in healthy animals. These results reveal a 
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pharmacological approach for overcoming cancer-induced functional limitations and the above 
noted cancer/drug-induced changes in muscle gene expression could be utilized as biomarkers of 
functional limitations.
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Introduction
Breast cancer is one of the most common cancers and a leading cause of cancer-associated 
morbidity/mortality in women worldwide (1). It is becoming increasingly clear that breast 
cancer is a systemic disease affecting multiple organs. The systemic effects of breast cancer 
are manifested in three distinct forms: functional limitation, sarcopenia, and cachexia (2-4). 
Functional Limitation, which is defined as muscle weakness and body pain with no obvious 
physical signs, is observed in 39% of breast cancer patients and is associated with increased 
risk of non-cancer cause of death (2). Functional limitation is found in women <40 ages 
even at the time of breast cancer diagnosis and before drug or surgical intervention (2,5). 
Sarcopenia (severe depletion of skeletal muscle, despite appearance of normal weight, 
overweight, or obesity) is observed in 25% of metastatic breast cancer patients and is 
associated with increased toxicity to chemotherapy (3). Additionally, 26% of breast cancer 
patients meet one of the four criteria of cachexia (4). Since onset of cachexia in breast 
cancer patients is not as rapid and progressive as in lung and pancreatic cancer, mechanistic 
studies on cachexia in breast cancer are limited. Acute cancer cachexia models used for 
mechanistic studies of cachexia in colon, pancreatic and lung cancers may not accurately 
reflect systemic impact of breast cancer. Therefore, model systems need to be developed to 
understand the systemic effects of functional limitations and sarcopenia in breast cancer and 
for the development of therapeutic strategies to treat these effects.
The main underlying pathophysiology of cancer-induced functional limitations/cachexia is 
thought involve the release of cytokines/chemokines such as tumor necrosis factor alpha 
(TNFα) and interleukin 1beta (IL-1β) from tumors that interfere with host immunity and 
skeletal muscle function (6). TNFα has been shown to impair muscle oxidative phenotype 
and cause muscle wasting (7). Thus, muscle wasting in advanced breast cancer may be due 
to potent catabolic effects of inflammatory cytokines through their downstream signaling. 
Muscle loss in cancer patients may be similar to age-associated muscle loss, which is 
accompanied with systemic inflammation and increased levels of cytokines including IL-1β, 
IL-6, IL-10, IL-13, TNFα and granulocyte-macrophage colony-stimulating factor (GM-
CSF) (8). NF-κB is a major signaling molecule downstream of, and, in some cases, 
upstream of these cytokines (9). NF-κB is not only critical in tumor initiation and 
progression as demonstrated by us and others (9,10), but also regulates skeletal muscle mass 
and function by reducing protein synthesis or enhancing degradation of myogenic 
transcription factors such as MyoD (11). Activation of NF-κB through muscle-specific 
transgenic expression of activated IκB kinase beta (IKKβ) causes profound muscle wasting 
that resembles clinical cachexia (12). Therefore, NF-κB has been proposed to be a potential 
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target for the treatment of loss of skeletal muscle mass in cancer cachexia (11,13). However, 
most of the studies that examined the role of NF-κB in cancer cachexia were done using 
acute models of cachexia (∼30 days) and it is yet to be ascertained whether these findings 
are relevant for breast cancer, which has a slower progression rate than other cancers, and 
usually does not display classic cachexia features.
Our previous study has shown that breast cancer patients with metastasis have lower level of 
circulating myogenic miR-486 (14). In line with human data, we observed that mice with 
mammary tumors have lower miR-486 concentrations in plasma and skeletal muscles (14). 
Mechanistic studies showed that tumor-induced cytokines such as TNFα and IL-1 are 
responsible for lower miR-486 expression in muscle cells. miR-486 is an integral part of a 
myogenesis signaling network that involves Pax7, MyoD, myostatin, and NF-κB (15-17) 
and MyoD actively induces its expression (17). In addition, miR-486 is essential for survival 
of cardiomyocytes since it blocks PTEN to upregulate PI3K/AKT (18). Furthermore, loss of 
miR-486 is a major defect in muscular dystrophy and transgenic expression of miR-486 in 
muscle can rescue muscular dystrophy phenotype in animal models (19). Considering the 
intricate network in muscle that involves both NF-κB and miR-486, this study aimed to 
determine whether pharmacological inhibition of NF-κB could overcome the cancer-induced 
musculoskeletal defects and expression of which among the genes within the broader NF-
κB-Pax7-MyoD-miR-486 signaling axis could be restored in muscle upon pharmacological 
inhibition.
We employed MMTV-PyMT transgenic mice (called PyMT+ mice hereafter) as an animal 
model of mammary tumors in order to characterize tumor progression and functional 
limitations (20). Genome-wide comparative analyses of multiple transgenic mammary tumor 
models have suggested PyMT+ model to represent the luminal B intrinsic subtype of breast 
cancer (21). We used dimethylaminoparthenolide (DMAPT), a water-soluble analogue of 
parthenolide, which we have previously shown to have potent NF-κB inhibitory activity (22) 
and has been shown to overcome the adverse effects of persistent activation of NF-κB in 
BRCA1-deficient mammary luminal progenitor cells in vivo (23). We found that mammary 
tumor development in PyMT+ mice was accompanied with functional limitations such as 
reduced grip strength, impaired rotarod balance, causing altered body composition as well as 
molecular changes in muscle including reduced expression of miR-486 and MyoD as we 
reported previously (14). Unlike in acute models of cachexia, which involves persistent 
expression of self-renewing factor Pax7 and block in myogenic differentiation (24), we 
observed lower Pax7 expression in muscle of PyMT+ mice. We also observed reduced 
expression of peroxisome-activated receptor coactivator 1-beta (Pgc-1β) in skeletal muscle 
of PyMT+ mice. MyoD, in combination with RelB, an alternative NF-κB, has been shown to 
maintain the expression of Pgc-1β in muscle and Pgc-1β is required for oxidative 
phosphorylation and mitochondrial biogenesis (25). DMAPT treatment ameliorates many of 
the functional limitations as well as the molecular changes in muscle including restoration of 
Pax7, MyoD, and Pgc-1β expression in muscle. These results have the potential for 
translation into a clinical strategy for targeting both tumors and functional limitations via 
inhibition of NF-κB to improve outcomes in breast cancer patients.
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Materials and Methods
Transgenic mice, functional limitation studies and drug treatment
National Institutes of Health regulations concerning the use and care of experimental 
animals were followed while conducting animal studies and the Indiana University School 
of Medicine animal use committee approved this study. Male PyMT+ mice on a FVB/N 
background were purchased from Jackson Laboratory, and randomly bred with non-
transgenic FVB/N females to obtain females heterozygous for the PyMT oncogene. Tumor 
progression was monitored periodically. Tumor volume was calculated as (length) × 
(width)2/2. Echo-MRI (Houston, TX) was used to determine body compositions. Grip 
strength was measured by laying mice on a wire mesh connected to a test meter (Bioseb), 
and pulling the tail directly back parallel to the mesh surface, then recording the amount of 
force. Three trials of each test were performed with minimal 5 min intervals and the average 
value from the three recordings is presented. For rotarod performance (Harvard Apparatus), 
the period of time mice were able to remain on a rotating rod at 10 rpm was recorded 3 times 
at minimum 5 min intervals and the average from the three recordings is presented. For the 
drug intervention study, DMAPT (100 mg/kg) or vehicle (2.5% mannitol) was orally 
administrated to mice from Monday to Friday, starting 6-8 weeks post birth until the end of 
the experiment. Age-matched normal female mice were used as controls. Structure of 
DMAPT has been described previously (26). Blood and the tissues were collected at the 
time of sacrifice as per the recommendation of the attending veterinarian for miRNA, 
mRNA and protein preparation or for histological analysis. Drug treated animals were 
sacrificed at two different time points; one time point set at the same age as the control mice 
with tumors and the second set as recommended by the attending veterinarian to measure 
biochemical parameters.
Sample processing miRNA and total RNA extraction
Mouse blood was collected in a K2 EDTA coated tube, which was centrifuged at 2000 rpm 
for 15 min at 4°C. Immediately following centrifugation, supernatant was transferred into a 
clean Eppendorf tube for storage at -80°C. A Qiagen miRNeasy serum/plasma kit was used 
to isolate miRNA from 200 μL of stored plasma (Qiagen #217184). Tibialis anterior and 
gastrocnemius muscles from the hind limb of the mouse were harvested, snap-frozen and 
stored in -80°C. A Qiagen miRNeasy Mini Kit (#217004) or Qiagen RNeasy Mini Kit 
(#74106) was used to isolate miRNA or total RNA for RNA amplification from ∼30 mgs of 
stored muscle. First, 700 μL QIAzol Lysis reagent/ or RLT lysis buffer was added to the tube 
containing dissected muscle, and the mixture then homogenized using a Qiagen TissueLyser 
LT unit with metal beads at a speed of 50Hz for 3 min, followed by 10 seconds sonication 
following the Qiagen recommended protocol.
Quantitative reverse transcription PCR
Five microliters of miRNAs extracted from plasma (20ng/μl) was used for cDNA synthesis 
using a Taqman miRNA Reverse Transcription Kit (Applied Biosystems). Total RNA from 
muscle tissues (200 ng/μl) were reverse transcribed into cDNAs using Bio-RAD iScript 
cDNA synthesis kit in a final volume of 20 μL. Quantitative PCR (qPCR) was performed 
using Taqman universal PCR mix (Applied Biosystems) and specific primers. miRNA 
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primers for U6 (#001973), miR-202 (#002579), miR-486 (#001278), miR-214 (#002293), 
miR-16 (#000391), miR-1(002222), miR-146a (000468), miR206 (#000510), and mRNA 
primers for Hsp90ab (#Mm00833431-g1), Pax7 (#Mm01354484-m1), MyoD 
(#Mm00440387-m1), Pgc-1β(#Mm00504730-m1), Acvr2b (#Mm00431664-m1), 
Dmpk(#Mm00446261-m1), Lmna(#Mm00497783-m1), Prkag1(#Mm00450298), Hoxa9 
(#Mm00439364), Mt1 (#Mm00496660-g1) and Mt2 (#mm00809556-s1), were purchased 
from Applied Biosystems. Pgc-1β primers amplify exons 11 and 12 and measure only the 
“A” isoform of Pgc-1β. Each amplification reaction was performed in duplicate in a final 
volume of 20 μL with 4 μL of cDNA. The expression levels of miR-486 were normalized to 
miR-202 (mouse sera) and U6 (skeletal muscle) using the 2−ΔΔCt method as described in a 
previous study (14).
Histological and immunohistochemical analysis
Tissues were immersed into 10% buffer formalin and stored in cold room. For H&E 
staining, formalin-fixed tissues were transferred to the pathology lab, paraffin-embedded, 
sliced, stained and analyzed by a pathologist. For immunofluorescence, formalin-fixed 
tissues were transferred to 20% sucrose in PBS over weekend, frozen, sliced with cryostat at 
10 micron, mounted on positively-charged slides, then washed with PBS three times, and 
incubated with Cox IV antibody (Abcam #ab16056; 1:1000). The next day, sections were 
washed three times with PBS and subsequently incubated with secondary antibody 
conjugated with a fluorescent dyes. After a final wash with PBS, sections were sealed by 
mounting media with DAPI, and viewed under fluorescent microscope. For ECM 
histochemical examination, formalin-fixed, frozen sliced sections were washed with PBS 
three times and then incubated with Texas-red-conjugated-wheat germ agglutinin (WGA) 
(Invitrogen, #W21405, 1:1000). WGA staining was quantified to measure ECM area by 
using Image J software. The area occupied by WGA was expressed relative to total area of 
the muscle cross-section.
Western blotting
Freshly harvested or frozen mouse muscles (∼30 mg tissue) was lysed in RIPA buffer with 
protease/phosphatase inhibitors (Sigma), then homogenized using Qiagen TissueLyser LT 
with metal beads at a speed of 50Hz for 3 min, followed by 10 seconds sonication. Thirty 
micrograms of proteins were used for Western blotting. Antibodies including mouse 
monoclonal Pax7 (Developmental Studies Hybridoma Bank, AB 528428) and MyoD 
(#sc-760, Santa Cruz Biotechnology) were used for Western blot analyses as per instructions 
from the manufacturers.
Cytokine measurements
Circulating cytokines were measured using 100μl of plasma and a MILLIPLEX MAP 
Mouse Cytokine/Chemokine Magnetic Bead Panel (MCYTMAG-70K-PX32, Millipore) that 
measures 32 cytokines/chemokines from limited samples. TGFβ1, 2 and 3 were measured 
separately. Each group contained plasma samples from six animals. Those samples with no 
detectable values were given a score of zero for the analyses.
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Statistical analysis
Multiple group data were compared using ANOVA. A P value of <0.05 was considered 
statistically significant.
Results
Tumor progression in PyMT+ transgenic mice is accompanied with functional limitations
PyMT+ transgenic mice develop mammary tumors at 100% penetrance (20). Palpable 
tumors in females were evident as early as 60 days with a slow progression (by volume) for 
the first few days followed by rapid tumor growth requiring animal sacrifice due to humane 
reasons within 2-3 weeks following tumor occurrence. During an observation period from 8 
to 14 weeks of age, we noted increased body weight in PyMT+ mice compared to control 
mice (Fig. 1A), which was significant by 12 weeks. While PyMT+ mice weighed 
26±0.7grams, the weight of control mice at the same age was 23± 0.4 grams. By 14 weeks, 
differences became even more significant with tumor-bearing mice reaching 30±1.1 grams, 
whereas control mice remained at 23±0.4 grams (Fig. 1A). This weight gain in PyMT+ mice 
is likely due to rapidly growing tumors.
We used echo-MRI to determine body composition. PyMT+ mice had significant loss of 
body fat with progressive disease compared to control mice (Fig. 1B). For instance, the 
percentage of body fat was 15±1.3% at the age of eight weeks in PyMT+ mice and 
significantly reduced to 10±0.5% at 14 weeks of age (Fig. 1B). In contrast to body fat, body 
lean mass increased with growth of tumors, and was particularly obvious at 14 weeks (Fig. 
1C). Parallel to the changes in body lean mass, the percentage of body free water and body 
total water increased in PyMT+ mice (Fig. 1D and 1E). This water retention may also have 
contributed to increased body weight in PyMT+ mice and could be the result of tumor-
induced impairment in lymphatic drainage. In line with body composition changes, we 
found that PyMT+ mice had reduced grip strength (Fig.1F). Eight-week old PyMT+ mice 
had 191±6.0 grams gripping force, which was further reduced to 162±6.6 grams and 
162±2.7 grams gripping force by 12 and 14 weeks, respectively. The gripping force in 
FVB/N wild type mice remained ∼200 grams during this observation period (Fig. 1F).
In order to test whether heart function was affected by mammary tumor burdens, we 
employed the ECGenie device to acquire ECG signals from live mice. Surprisingly, tumor 
burden did not significantly change heart beating intervals and heart beating rate 
(Supplementary Fig. 1). One reason for the lack of effects on cardiac function could be the 
rapid tumor growth forcing animal sacrifice before any cardiac effects of tumor burden were 
noticeable with available measurement tools.
DMAPT inhibits mammary tumors in PyMT+ mice
To investigate whether NF-κB is the central node in cancer-induced systemic effects, we 
treated PyMT+ mice with the NF-κB inhibitor DMAPT. DMAPT is a water-soluble 
analogue of parthenolide, an active ingredient of the herb feverfew (22,27). As with many 
targeted therapies, DMAPT displays NF-κB-dependent and NF-κB-independent activities; 
however, its major therapeutic effects are likely through NF-κB inhibition (22). Treatment 
Wang et al. Page 6
Mol Cancer Ther. Author manuscript; available in PMC 2018 June 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
with DMAPT (100mg/kg, 5 times/week, orally), starting at 6-8 weeks of age, prior to visual 
appearance of mammary tumors, delayed mammary tumor visual onset and slowed tumor 
growth rates compared to vehicle treatment (Supplementary Table S1). At 10 weeks, 60% of 
PyMT+ mice with vehicle treatment had developed mammary tumors, while only 10% of 
PyMT+ mice with DMAPT treatment had mammary tumors. By 12 weeks, tumor burden 
was 3.6±1.2 cm3 in mice treated with vehicle, while it was 0.7±0.3 cm3 in mice with 
DMAPT treatment. These differences in tumor growth persisted until the termination of the 
study. Tumor burden was 10.6 ±1.6 cm3 in mice treated with vehicle treatment vs. 6.3±1.3 
cm3 in mice treated with DMAPT by 14 weeks (Supplementary Table S1). Tumors of 
DMAPT-treated animals compared to tumors from vehicle-treated animals contained ∼40% 
lower levels of transcripts for IL-6 (p=0.006), a NF-κB target gene, suggesting that the drug 
is targeting NF-κB in tumors. These differences in tumor growth/characteristics also 
translated into time of sacrifice of animals as recommended by the attending veterinarian. 
By this measurement, overall survival of animals in DMAPT treated group was significantly 
longer compared to control mice (Fig. 2A). For the purpose of tissue collection, we repeated 
the experiment with control and drug-treated groups and collected tissues at the same age 
point. Lungs from non-transgenic, PyMT+, and PyMT+ + DMAPT mice that were harvested 
at the same age as well as another group of control, untreated and drug-treated PyMT+ 
animals, which were allowed to survive until recommended for euthanasia by the attending 
veterinarian, were examined for metastasis. Surprisingly, despite reduced tumor growth and 
improved survival, DMAPT-treated animals showed similar metastasis burden as untreated 
PyMT+ mice (Fig. 2B). Note that all FVB/N background wild type mice did not develop 
mammary tumors during the entire period of these observations (Table S1).
DMAPT restores functional performance in PyMT+ mice
We next examined function limitations including grip strength and rotarod performance. We 
observed that both vehicle and DMAPT treated mice had significantly lower gripping force 
to the metal wires of the test meter at 12 and 14 weeks of age compared to control mice. 
However, gripping force of DMAPT-treated mice was significantly better than vehicle-
treated mice (Fig 3A). For instance, vehicle-treated mice had a gripping force of 159±3.9 g, 
while mice that received DMAPT had gripping force of 193±3.9 g. In addition, PyMT+ mice 
that received DMAPT treatment had better rotarod performance. In the rotarod test, FVB/N 
wild type mice rotarod performance was 113±21 seconds, while PyMT+ mice with vehicle 
could only hold on to the rotating rod for 11.6±2.7 seconds. DMAPT treated mice stayed on 
the rod for 37±9.7 seconds (Fig. 3B).
To examine whether DMAPT ameliorates alterations of body composition associated with 
mammary tumors in PyMT+ mice, we monitored body weight, body fat, body lean mass, 
body free water, and body total water every other week utilizing echo-MRI analysis (Fig. 
3C-3F). Both vehicle and DMAPT treated mice exhibited similar trend of changes in body 
composition in the three categories of body fat, body lean mass and total body water, but not 
in body free water (Fig. 3C-3F). There was a significant increase of body free water in mice 
treated with vehicle, but in mice treated with DMAPT body free water was significantly 
lower and similar to levels in non-transgenic wild type mice (Fig. 3E). In addition, DMAPT-
treated mice gained less weight when compared to vehicle-treated mice (Fig. 3G).
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Restoration of muscle function by DMAPT is accompanied with reversal of several cancer-
induced molecular changes in skeletal muscle
To associate the beneficial effects of DMAPT with specific changes in molecular 
parameters, we measured the levels of skeletal-muscle enriched microRNAs in the 
circulation and in muscle. Consistent with our previous report (14), plasma miR-486 levels 
were lower in tumor-bearing mice compared to control mice (Fig. 4A). To our surprise, 
DMAPT treatment did not significantly restore circulating miR-486 levels despite improving 
muscle function. However, we found elevated levels of circulating miR-146a in animals 
treated with DMAPT. miR-146a, although NF-κB inducible, plays a major role in 
attenuating inflammation by targeting molecules in NF-κB regulatory network including 
cytokine receptors, thus reducing cytokine action and NF-κB activity (28).
We next examined miR-486 levels in muscles. miR-486 levels in the muscle of PyMT+ mice 
were lower compared to control mice (Fig. 4B), similar to our previous observations (14). 
As with circulating miR-486, DMAPT-treatment did not restore muscle miR-486 (Fig. 4B). 
Thus, it appears that DMAPT restores muscle function that is independent of miR-486. 
miR-206 is another muscle-specific microRNA and inflammatory cytokines reduce its 
expression to promote muscle degeneration, inflammatory myopathies, and dermatomyositis 
(15,29,30). In addition, miR-206, secreted by myogenic progenitor cells, control 
extracellular matrix deposition (31). We measured miR-206 levels in muscle to further 
document the effects of cancer progression on muscle. Indeed, miR-206 levels in muscle 
were lower in PyMT+ mice compared to control mice (Fig. 4B). Among other muscle-
related microRNAs, we observed down-regulation of miR-214 but not miR-1 in skeletal 
muscle of PyMT+ mice compared to control mice (Fig. 4B). Surprisingly, DMAPT failed to 
change the expression levels of any of these microRNAs. We noted that although circulating 
levels of miR-146a were elevated in DMAPT-treated animals, the levels did not change in 
muscle suggesting that muscle is not the source of circulating miR-146a in DMAPT-treated 
animals.
DMAPT restores loss of Pax7, MyoD, Hoxa9, and Pgc-1β in skeletal muscles of PyMT+ mice
To determine whether enhanced functional performance upon DMAPT treatment can be 
correlated with the expression levels of other NF-κB targets, we first measured Pax7 protein 
levels in skeletal muscles. We found lower levels of Pax7 protein in muscle of PyMT+ mice 
compared to wild type mice, and DMAPT restored Pax7 levels in tumor-bearing mice to 
levels similar to wild type mice (Fig. 5A). Consistent with protein analysis, qRT-PCR 
showed lower levels of Pax7 mRNA in PyMT+ mice and the reverse in DMAPT-treated mice 
(Fig. 5B).
We also observed lower MyoD protein level in skeletal muscles of PyMT+ mice compared to 
control mice although these differences did not reach statistical significance (p=0.13). 
However, MyoD protein levels in DMAPT treated animals were significantly higher than in 
untreated animals, suggesting that NF-κB inhibition can lead to elevated MyoD levels in 
muscle (p=0.01; Fig. 5A). As with protein levels, MyoD mRNA levels were lower in the 
muscle of PyMT+ mice (Fig. 5B) but DMAPT treatment only marginally increased MyoD 
mRNA levels. Thus, it appears that DMAPT likely reduces MyoD protein turnover.
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To identify additional targets of DMAPT, we performed Myogenesis and Myopathy PCR 
array (Qiagen) covering >90 muscle-enriched genes using skeletal muscle RNA from 
control, PyMT+ and PyMT++DMAPT mice (n=5/group). Compared to control mice, only 
six genes in this panel showed significantly lower expression in muscle of PyMT+ mice and 
none showed elevated expression (AcvR2b, Dmpk, Il-1β, Lmna, Nos2 and Prkag1, 
Supplemental Table S2). In DMAPT-treated mice, only Dmpk mRNA levels remained lower 
compared to control animals. In validation experiments, while AcvR2b, Dmpk, Lmna and 
Prkag1 mRNA levels remained low in the skeletal muscle of tumor-bearing animals, 
DMAPT failed to improve their expression levels. Thus, among myogenesis-associated 
genes, DMAPT was only able to restore the expression of only Pax7 and MyoD.
We examined the expression levels of four other genes associated with NF-κB signaling and 
are also recently been linked to metabolism, differentiation, and aging of muscle. These 
include Pgc-1β, which is induced by MyoD and alternate NF-κB, and is a negative regulator 
of canonical NF-κB signaling in skeletal muscle (25,32), Hoxa9, which is typically elevated 
in aging satellite cells of muscle and its expression is repressed by NF-κB (33,34), and 
metallothioneins 1 and 2 (Mt1 and Mt2), which control skeletal muscle mass and strength 
(35). Pgc-1β and Hoxa9 but Mt1 and Mt2 mRNA levels were lower in the skeletal muscle of 
tumor-bearing mice, which were reversed upon DMAPT treatment (Fig. 5B). Thus, DMAPT 
restored the expression of four proven targets of NF-κB in muscle (i.e. Pax7, MyoD, Pgc-1β, 
and Hoxa9).
DMAPT reverses cancer-induced loss in muscle mitochondria—Pgc-1β is 
necessary for oxidative phosphorylation and mitochondria biogenesis (25). Since Pgc-1β 
levels were lower in skeletal muscle of PyMT+ mice, we next determined mitochondria 
content by staining for Cox IV, which is a mitochondria-enriched protein. Skeletal muscle of 
PyMT+ mice contained lower levels of Cox IV compared to control mice and DMAPT 
treatment restored Cox IV levels (Fig. 6A). Thus, cancer-induced loss of Pgc-1β has an 
effect on mitochondria biogenesis in muscle, which may be a contributing factor for 
weakened muscle function.
DMAPT attenuates extracellular matrix deposition in skeletal muscles of 
PyMT+ mice—The extracellular matrix (ECM) provides an appropriate and permissive 
environment for muscle development and functioning (36). Dynamic remodeling of the 
ECM is directed by the activity of matrix metalloproteinases such as MMP9, which is a 
known transcriptional target of NF-κB (37). Moreover, enhanced satellite cell to myogenic 
progenitor cell differentiation leads to increased ECM accumulation in muscle (31). Since 
muscle of tumor-bearing mice expressed low levels of the two satellite-specific transcription 
factors Pax7 and Hoxa9, which could be due to enhanced satellite cell to progenitor cell 
differentiation, we determined ECM composition in muscle. PyMT+ mice had twice the 
level of ECM compared to control mice and this increase was blocked by DMAPT (Fig. 6B). 
Interestingly, H&E staining of muscles did not reveal morphological difference of muscle 
fibers and muscle fiber sizes among three groups under basic light microscope examination 
(Fig. 6C). Thus, cancer progressions in PyMT+ mice is associated with molecular changes in 
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muscle, which may not be manifested at morphological levels but likely have consequential 
effects on muscle function.
DMAPT alters circulating cytokines/chemokines—We used a Bio-Plex 200 bead-
based suspension system (Luminex platform) to determine tumor-induced changes in 
circulating cytokines/chemokines and to determine the effect of DMAPT treatment on their 
levels. Expression levels of seven (GM-CSF, TNFα, TGFβ2, TGFβ3, IL-6, VEGF, and G-
CSF) were elevated and six (LIX, IL-1α, KC, IL-9, MIP-2, and TGFβ1) were decreased in 
PyMT+ mice compared to control mice (Fig. 7, Supplementary Table S3 for raw data). 
DMAPT reversed cancer-induced changes in the expression of six of these cytokines (i.e. 
LIX, IL-1α, IL-9, MIP-2, TGFβ1, and GM-CSF). Among the cytokines whose expression 
was unaffected by tumors, DMAPT reduced the levels of IL-5 and MIP-1b. Collectively, 
these results demonstrate unique effects of PyMT-derived tumors on circulating cytokines/
chemokines levels and pharmacologic approaches to circumvent these changes.
Discussion
Functional limitations and sarcopenia are the validated systemic effects of breast cancer 
(5,38). However, to our knowledge, none of the currently available transgenic models have 
been used to understand these systemic effects and to test for therapies that have dual effects 
on cancer and systemic effects or that may complement chemotherapy to improve quality of 
life. Numerous cachexia models have been developed over the years but most of these 
involve xenograft models with acute onset of cachexia (39,40). We initiated this study with 
three goals; 1) to determine whether transgenic models of breast cancer mimic functional 
limitations observed in patients; 2) If so, what are the molecular changes in muscle that 
accompany mammary tumor progression?; and 3) Can these models be used to identify 
therapies that might overcome systemic effects with or without anti-tumor effects. Our 
results clearly show that PyMT+ mice develop functional limitations, which are 
accompanied with molecular changes in skeletal muscle, particularly the expression levels of 
satellite cell-specific transcription factors. Since many cancer patients experience 
parainflammation of epithelial origin and cytokines involved in this parainflammation can 
have paracrine effects on muscle (41), drugs that inhibit the function of cytokines could be 
effective in reducing cancer-associated systemic effects. The drug DMAPT inhibits NF-κB 
signaling downstream of many cytokines (22,27,42) and was effective in reducing systemic 
effects of mammary tumor. Although part of the benefits of DMAPT treatment on muscle 
function can be attributed to reduced tumor burden, we believe that the drug had additional 
direct effects on skeletal muscle. Untreated and DMAPT-treated mice showed similar 
metastatic burden, which indicates that the drug only limits the primary tumor growth and 
paracrine factors from metastasis that mediate systemic effects remain the same in untreated 
and drug-treated groups. In addition, circulating levels of several cytokines, particularly G-
CSF, which promotes breast cancer metastasis through neutrophil polarization (43), were 
elevated in PyMT+ mice and were unaffected by DMAPT treatment. The failure of DMAPT 
as a single agent to inhibit metastasis is not unexpected and is consistent with our previous 
report using parthenolide in xenograft models (44). However, the primary-tumor specific 
effect of the drug provides support for the recent observation that early dissemination seeds 
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metastasis and metastasis evolves independent of primary tumor with distinct signaling 
networks (45).
Genes that undergo changes in expression in cancer-associated skeletal muscle can be 
classified into two groups; one group of DMAPT-responsive genes that is integral to the NF-
κB pathway, and the other DMAPT- insensitive group. The DMAPT-sensitive group 
included genes/proteins in the muscle satellite cell function including Pax7 and Hoxa9. We 
observed that the levels of both of these genes being lower in muscle of tumor-bearing mice 
compared to wild type mice. Hoxa9 deregulation in muscle has been studied in the context 
of aging but not functional limitation and the current study is the first report to show tumor-
induced loss of Hoxa9 expression in muscle (33). Our observation on Pax7 depletion in the 
muscle of tumor-bearing transgenic mice is different from the observed accumulation of 
Pax7 in muscle under acute cachexia due to block in satellite cell differentiation (24). In this 
respect, the duration of the experiment may have contributed to these disparate results. The 
fact that both Pax7 and the other satellite factor Hoxa9 are reduced in muscle in our model 
clearly suggests that cancer advances aging of muscle. In this respect, we also observed 
increased circulating level of GM-CSF in PyMT+ mice, which previously has been shown to 
mediate age-associated muscle loss in elderly patients (8). The reduction in MyoD and 
Pgc-1β in skeletal muscle of tumor-bearing mice is similar to reports in acute models of 
cachexia (46,47).
The set of down-regulated genes in skeletal muscle of PyMT+ mice compared to wild type 
mice and that are insensitive to DMAPT include Acvr2b, Dmpk and Prkag1 and microRNAs 
miR-486 and miR-206. Activin type II receptor (Acvr2b) regulates skeletal muscle growth 
by binding with its ligands such as myostatin or activin (48). Myotonic dystrophy protein 
kinase (Dmpk) is a Ser/Thr protein kinase, mainly expressed in smooth, skeletal and cardiac 
muscles. Decreased Dmpk protein levels may contribute to the pathology of Myotonic 
Dystrophy, as revealed by gene targeting studies (49). Protein kinase AMP-activated non-
catalytic subunit gamma 1 (Prkag1) is the regulatory subunit of AMP-activated protein 
kinase (AMPK), which is an important energy-sensing enzyme that monitors cellular energy 
status (50). Failure of DMAPT to restore the expression of these genes/microRNAs could be 
the reason for partial recovery of functional limitations and additional agents that restore the 
expression and/or function of these genes may provide better protection against cancer-
induced systemic effects.
Our studies show that DMAPT had an effect outside the muscle tissue, which may have 
helped in reversing systemic effects of cancer and reversing NF-κB-driven inflammation. 
We observed elevated levels of miR-146a in the circulation but not in muscle of PyMT+ 
mice treated with DMAPT. miR-146a attenuates the inflammatory response by targeting 
cytokine receptors that promote NF-κB-driven inflammation (51) and its upregulation in 
circulation of DMAPT-treated mice through an unknown mechanism and from an unknown 
source indicates treatment-induced attenuation of inflammation (28). Elevated miR-146a 
levels may also be responsible for restored muscle function in DMAPT-treated mice despite 
the failure of the drug to reduce the levels of pro-inflammatory cytokines such as TNFα, 
IL-6, TGFβ2, TGFβ3, and G-CSF, many of which have been linked to cancer-induced 
changes in skeletal muscle function in at least in vitro studies (39). These results also 
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highlight the difficulty in translating results from in vitro studies that show the effect of 
these cytokines on skeletal muscle differentiation into the in vivo condition.
In summation, this report documents skeletal muscle changes in a chronic mammary tumor 
model that represents a luminal B intrinsic subtype of breast cancer that are partially 
different from changes observed in acute tumor/cachexia models, and the feasibility of 
reversing these changes by utilizing drugs with NF-κB inhibitory activity. Circulating 
miR-146a and GM-CSF levels as well as expression levels of Pax7, Hoxa9, MyoD, Pgc-1β 
and Cox IV in muscle could be used as biomarkers to document cancer-induced functional 
limitations and the specificity of drugs that overcome functional limitations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Characterization of systemic effects of mammary tumors in PyMT+ mice. A) Body weight. 
B) Percentage of fat over total body weight. C) Percentage of lean mass over total body 
weight. D) Percentage of body free water over total body weight. E) Percentage of total 
body water over total body weight. F) Grip strength. * indicates significance between 
PyMT+ and wild type groups, p<0.05. # indicates significance between baseline (eight 
weeks) and experimental data from the same group, p<0.05. n= 5 (wild type) and 8 (PyMT+) 
mice/group.
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Figure 2. 
The effect of DMAPT on survival and metastasis. A) Oral administration of DMAPT 
(100mg/kg, M-F/week, starting at 6-8 weeks age) improves survival. (B) Left panel images 
show representative lung metastasis and right graph shows average lung metastasis area per 
mouse. n=5 mice/group. Note that this analysis included two sets of mice; lungs from age-
matched untreated and DMAPT-treated animals and from animals collected at the end of the 
terminal experiments. In both sets, there were no statistical differences in rate of metastasis 
between groups, although there was a trend of lower metastasis in the DMAPT-treated 
group.
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Figure 3. 
Oral administration of DMAPT (100mg/kg, M-F/week) modulates body composition and 
functional performance in PyMT+ mice. A) DMAPT restores grip strength. B) DMAPT 
partially ameliorates tumor-induced decline in rotarod performance. C) DMAPT treatment 
does not alter tumor-induced loss of fat. D) DMAPT has minimal effect on tumor-induced 
changes in body lean mass. E) DMAPT reduces percentage of body free water. F) DMAPT 
does not significantly change total body water ratio. g) DMAPT slows down body weight 
gain. * indicates significance between experimental groups and wild type group, p<0.05. # 
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indicates significance between PyMT+ group with vehicle and with DMAPT treatments at 
same age-testing point, p<0.05. n= 10 mice/group.
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Figure 4. 
The effect of DMAPT on cancer-induced changes in circulating and muscle-enriched 
microRNAs. A) The effect of DMAPT on circulating miRNAs. miR-486 levels were lower 
in plasma of PyMT+ mice, which remained low in DMAPT-treated mice. DMAPT increased 
circulating miR-146a levels. B). DMAPT treatment did not restore tumor-induced loss of 
muscle-enriched microRNAs in hind limb muscle of PyMT+ mice. Average and standard 
deviation are shown. * indicates significance between experimental and wild type groups, 
p<0.05. n= 8-10 mice/group.
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Figure 5. 
DMAPT restores tumor-induced loss of Pax7, MyoD and Pgc-1β in skeletal muscle. A) 
Pax7 and MyoD protein levels. Left panel images show Pax7 and MyoD protein in skeletal 
muscles of hind limbs. Image J was used to quantitate Western blotting data (right panel). B) 
qRT-PCR analysis of multiple mRNAs in skeletal muscles of PyMT+ mice. Eight of 10 
analyzed mRNAs are downregulated in muscle whereas two of 10 mRNAs are not changed 
in PyMT+ mice compared to wild type mice. DMAPT treatment significantly reversed 
tumor-induced loss of Pax7, Pgc-1β and Hoxa9 mRNA levels. * indicates significance 
between experimental and wild type groups, p<0.05. # indicates significance between 
vehicle-treated and DMAPT-treated PyMT+ animals. p<0.05. n= 8-10 mice/group.
Wang et al. Page 21
Mol Cancer Ther. Author manuscript; available in PMC 2018 June 01.
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
VA A
uthor M
an
u
script
Figure 6. 
Cox IV, ECM, and muscle fiber length changes in skeletal muscle of transgenic mice. A) 
Cox IV levels, a Pgc-1β target, in muscle. Cox IV levels were measured by 
immunofluorescence and quantitated using Image J. B) Deposition of extracellular Matrix 
(ECM) in skeletal muscle of PyMT+ mice. Top images show histochemical staining by 
Texas-red-conjugated-wheat germ agglutinin in skeletal muscle of mice, whereas bottom 
graph shows quantification of ECM by Image J. C) Analysis of skeletal muscle in hind limb 
of mice. Top images show H&E staining of quadriceps, whereas bottom graph shows 
analysis of average area of cross section of each skeletal muscle fiber from quadriceps. * 
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indicates significance between experimental and wild type groups, p<0.05. # indicates 
significance between vehicle-treated and DMAPT-treated PyMT+ animals. p<0.05. n= 5-6 
mice/group.
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Figure 7. 
DMAPT alters circulating levels of select cytokines/chemokines. Cytokine/chemokine levels 
were measured by multiplex ELISA using plasma from age-matched animals of three groups 
(n=6). A value of zero was given to cases with no detectable cytokine/chemokine content. 
Only data with at least three animals per group with detectable expression are included. Data 
are graphed as three panels based on cytokine/chemokine levels. * and ** indicates 
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significance between experimental and wild type groups, p<0.05; **p<0.001. # indicates 
significance between vehicle-treated and DMAPT-treated PyMT+ animals. p<0.05.
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